The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1295
September 22, 2008
View Complete Issue         Table of Contents 2019 
Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension
September 22, 2008 (Issue: 1295)
Clevidipine (Cleviprex - The Medicines Company), a dihydropyridine calcium channel blocker (CCB), has been approved by the FDA for intravenous (IV) use in lowering high blood pressure. It is the second IV CCB to be marketed in the US; nicardipine has...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension
Article code: 1295a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.